FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and immunology. Antibody able to bind certain section of glypican-3 is disclosed, as well as humanized antibody, created on basis of this antibody. Antibody to GPC3 according to this invention has higher ADCC activity and CDC activity compared to traditional antibody.
EFFECT: antibody by present invention can be used as cell growth inhibitor, anticancer agent and means for diagnostics of cancer.
3 cl, 20 dwg, 1 tbl, 27 ex
| Title | Year | Author | Number |
|---|---|---|---|
| GLYPICAN-3 ANTIBODY | 2005 |
|
RU2427588C2 |
| CELL DAMAGE INDUCING THERAPEUTIC MEDICINAL PRODUCT FOR ANTICANCER THERAPY | 2017 |
|
RU2746754C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2812875C1 |
| MEDICATION FOR TREATMENT OF LIVER CANCER | 2009 |
|
RU2523897C2 |
| GPC3-TARGETED DRUG WHICH IS ADMINISTERED TO PATIENT SENSITIVE TO GPC3 DRUG-TARGETING THERAPY | 2013 |
|
RU2707882C2 |
| GLYPICAN-3 ANTIBODY AND USE THEREOF | 2016 |
|
RU2744245C2 |
| ANTI-GLYPICAN 3-ANTIBODY HAVING MODIFIED SUGAR CHAIN | 2005 |
|
RU2451030C2 |
| ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | 2014 |
|
RU2675516C2 |
| MEDICINAL AGENT CONTAINING PHOSPHOLIPASE D4 ANTIBODY | 2014 |
|
RU2709741C2 |
| MODIFIED EXOTOXIN A PSEUDOMONADES | 2014 |
|
RU2687143C2 |
